- Home
- TDC vs HCM Comparison
TDC vs HCM Comparison
Compare TDC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | HCM |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2007 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TDC | HCM |
|---|---|---|
| Price | $32.15 | $14.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $33.50 | $20.59 |
| AVG Volume (30 Days) | ★ 1.4M | 47.0K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.38 | N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,156,000,000.00 | N/A |
| Revenue This Year | N/A | $14.24 |
| Revenue Next Year | $1.33 | $11.52 |
| P/E Ratio | $7.88 | ★ $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.54 | $9.77 |
| 52 Week High | $41.78 | $16.33 |
Technical Indicators
Market Signals| Indicator | TDC | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 59.72 | 54.95 |
| Support Level | $30.36 | $13.93 |
| Resistance Level | $32.03 | $14.44 |
| Average True Range (ATR) | 0.95 | 0.35 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 81.25 | 53.94 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.